Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

MASLD, a liver disease linked to obesity and poor lifestyle, is rising among children. Often symptomless early on, it can ...

With increasing awareness about the need to manage obesity—a global epidemic—launch of weight-loss injections in India and public demand for tailored treatment, hospitals in Delhi-NCR are stepping up ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Insurance companies should not drag their feet. They must take meaningful steps to ensure that obesity treatment is easily ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...

Danish pharmaceutical company Novo Nordisk on Tuesday launched its once-weekly injectable weight-loss drug Wegovy in India, at Rs 4,336.25 per dose. Wegovy, a once-weekly glucagon-like peptide-1 ...

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is ...

Nearly half of Indian women aged 35–49 are overweight or obese. Experts say recognising obesity as a disease and addressing stigma, bias and all health factors is key to effective treatment ...

Go to source). While obesity is a global issue, the Indian experience is shaped quite literally by a different curve: abdominal obesity, also known as central obesity.